Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions.
WHY WE'RE FUNDRAISING WITH THE JIMMY FUND WALK TO FIGHT CANCER
Dear Friends and Family: Our son, grandson and nephew Ollie has been fighting ATRT since he was diagnosed at nine months old. He has been living with this horrible disease, and the effects of treatment, all while maintaining his wonderful smile and joyful demeanor. He is a smart, happy, funny and beautiful toddler. He is so social and is known to blow his nurses kisses. He loves music, his baby brother, his cat and so much more. There are too many kids fighting with ATRT along with Ollie. We've also lost too many friends along this journey. We pray every single day for a cure and that one day treatment for ATRT will be easier and more successful. In celebration of our Ollie, we invite you to consider making a donation in his honor to fund ATRT research. We thank you for all the love and support you have shared since his diagnosis. We send love to you all.
Dana-Farber has long led the way in uncovering more impactful therapies for ATRT. However, ATRT remains a very difficult tumor to cure, and the identification of new therapies and drug targets is a high priority in the field.
Dr. Susan Chi is an oncologist in Dana-Farber’s Pediatric Brain Tumor Center and a world expert in the treatment of children with ATRT. She develops and leads clinical trials and also partners with researchers to discover new treatments and improve the overall survival and quality of life for patients like Ollie.
One of her collaborators is Dr. Mariella Filbin, who runs a lab at Dana-Farber focused on finding new potential treatments for some of the most difficult brain tumors, including ATRT. Dr. Filbin is specifically pioneering the use of a technology called single cell sequencing to reveal the individual identity of each cell within an ATRT tumor. Ultimately, she hopes that her work will help to stratify treatment and determine whether certain subgroups of ATRT should be treated more aggressively to improve overall response to treatment.
The work of experts like Dr. Chi and Dr. Filbin is not possible without the generosity of donors. Your gift will directly advance their efforts.
Dear Friends and Family: Our son, grandson and nephew Ollie has been fighting ATRT since he was diagnosed at nine months old. He has been living with this horrible disease, and the effects of treatment, all while maintaining his wonderful smile and joyful demeanor. He is a smart, happy, funny and beautiful toddler. He is so social and is known to blow his nurses kisses. He loves music, his baby brother, his cat and so much more. There are too many kids fighting with ATRT along with Ollie. We've also lost too many friends along this journey. We pray every single day for a cure and that one day treatment for ATRT will be easier and more successful. In celebration of our Ollie, we invite you to consider making a donation in his honor to fund ATRT research. We thank you for all the love and support you have shared since his diagnosis. We send love to you all.
Dana-Farber has long led the way in uncovering more impactful therapies for ATRT. However, ATRT remains a very difficult tumor to cure, and the identification of new therapies and drug targets is a high priority in the field.
Dr. Susan Chi is an oncologist in Dana-Farber’s Pediatric Brain Tumor Center and a world expert in the treatment of children with ATRT. She develops and leads clinical trials and also partners with researchers to discover new treatments and improve the overall survival and quality of life for patients like Ollie.
One of her collaborators is Dr. Mariella Filbin, who runs a lab at Dana-Farber focused on finding new potential treatments for some of the most difficult brain tumors, including ATRT. Dr. Filbin is specifically pioneering the use of a technology called single cell sequencing to reveal the individual identity of each cell within an ATRT tumor. Ultimately, she hopes that her work will help to stratify treatment and determine whether certain subgroups of ATRT should be treated more aggressively to improve overall response to treatment.
The work of experts like Dr. Chi and Dr. Filbin is not possible without the generosity of donors. Your gift will directly advance their efforts.